10-K: Silence Therapeutics Reports Full Year 2024 Results, Highlights Progress in Clinical Programs and Phase 3 Readiness

Silence Therapeutics reports its full year 2024 results, showcasing advancements in its clinical programs and preparations for Phase 3 trials.

Summary

• Silence Therapeutics, a biotechnology company, reported its financial results for the year ended December 31, 2024.
• The company is focused on discovering and developing siRNA therapeutics, with its pipeline targeting cardiovascular, hematology, and rare diseases.
• Key product candidates include divesiran (SLN124) for polycythemia vera (PV) and zerlasiran (SLN360) for cardiovascular disease associated with elevated Lp(a).
• Positive interim results from the Phase 1 portion of the SANRECO clinical trial of divesiran in PV patients were presented at the ASH annual meeting in December 2024.
• The first subject has been dosed in the Phase 2 portion of the SANRECO clinical trial, with full enrollment anticipated by year-end 2025.
• Positive regulatory feedback was received from the FDA and EMA on the Phase 3 cardiovascular outcomes study design for zerlasiran in patients with high Lp(a).
• The company is engaged in global partnership discussions to seek a third-party partner for potential Phase 3 development of zerlasiran.
• A Phase 1 clinical trial for a third siRNA product candidate from the mRNAi GOLD platform is underway through a collaboration with AstraZeneca.
• Hansoh notified Silence Therapeutics that it will not pursue further development under the Hansoh Collaboration.
• The company had cash, cash equivalents, and short-term investments of $147.3 million as of December 31, 2024, which is expected to fund operations into 2027.
• Net losses were $45.3 million for the year ended December 31, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive developments in the clinical pipeline and partnerships, the company continues to experience net losses and faces various risks and challenges.

Positives

• Divesiran received Fast Track and orphan drug designations from the FDA and orphan drug designation from the European Commission for PV.
• Zerlasiran has shown the potential to substantially reduce Lp(a) levels in ASCVD patients, with maximum reductions exceeding 90% during the treatment period and effects persisting 60 weeks following first dose.
• The company has a third siRNA product candidate in Phase 1 development through its collaboration with AstraZeneca.
• The company believes that its current cash and cash equivalents and short-term investments will be able to fund its operations into 2027.

Negatives

• The company has a history of net losses and anticipates continuing to incur significant losses for the foreseeable future.
• The company has never generated any revenue from product sales and may never be profitable.
• Hansoh notified Silence Therapeutics that it will not pursue further development under the Hansoh Collaboration.

Risks

• The company will require additional financial resources to continue the ongoing development of its product candidates and pursue its business objectives.
• The approach the company is taking to discover and develop drugs is novel and may never lead to marketable products.
• The company relies on third parties to conduct some aspects of its manufacturing, research and development activities, and those third parties may not perform satisfactorily.
• Even if the company completes the necessary preclinical studies and clinical trials, it cannot predict whether or when it will obtain regulatory approval to commercialize a product candidate.
• The company faces competition from other companies that are working to develop novel drugs and technology platforms using technologies similar to its.
• If the company fails to introduce new products or keep pace with advances in technology, its business, financial condition and results of operations could be adversely affected.
• The company faces potential product liability and other claims, and, if successful claims are brought against it, it may incur substantial liability and costs.
• Cybersecurity risks and the failure to maintain the confidentiality, integrity, and availability of the company's computer hardware, software, data and internet applications and related tools and functions, or those of third parties with whom it works, could result in damage to its reputation and/or subject it to costs, fines or lawsuits.
• The company and the third parties with whom it works are subject to stringent and evolving U.S. and foreign data privacy and security laws, regulations contractual obligations, industry standards, policies, and other obligations, and its (or the third parties with whom it works) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class actions); fines and penalties; disruptions of its business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.
• If the company is unable to obtain or protect intellectual property rights related to its current or future products and product candidates, it may not be able to compete effectively in its markets.
• The company may be involved in lawsuits to protect or enforce its patents or the patents of its licensors, which could be expensive, time-consuming and unsuccessful.
• The transition from foreign private issuer to U.S. domestic issuer status effective from January 1, 2025, requires the company to comply with the U.S. domestic reporting requirements under the Exchange Act and will result in significant additional compliance activity and increase its costs and expenses.
• The company no longer qualifies as an emerging growth company as of December 31, 2024, and, as a result, it will no longer be able to avail itself of certain reduced reporting requirements applicable to emerging growth companies.
• The company has incurred and will continue to incur increased costs as a result of operating as a public company, and its management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices.
• The trading price of the company's ADSs may be volatile, and you could lose all or part of your investment.
• Future sales, or the possibility of future sales, of a substantial number of the company's ADSs could adversely affect the price of such securities.
• The company may identify material weaknesses in its internal control over financial reporting. If it experiences material weaknesses or significant deficiencies in the future or otherwise fail to maintain an effective system of internal controls, it may not be able to accurately or timely report its financial condition or results of operations, which may adversely affect its business.
• Holders of the company's ADSs have fewer rights than its shareholders and must act through the depositary to exercise their rights.
• If a United States person is treated as owning at least 10% of the company's ordinary shares, such United States person may be subject to adverse U.S. federal income tax consequences.
• Claims of U.S. civil liabilities may not be enforceable against the company.
• The company's articles of association provide that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.

Future Outlook

The company expects its existing capital resources to be sufficient to fund its operations, including currently anticipated research and development activities and planned capital spending, at least for the next twelve months. The company believes that its current cash and cash equivalents and short-term investments will be able to fund its operations into 2027.

Industry Context

The announcement highlights Silence Therapeutics' focus on RNAi therapeutics, a rapidly evolving field with the potential to transform the treatment of genetic and other diseases. The company's progress in clinical trials and partnerships positions it as a key player in this competitive landscape.

Comparison to Industry Standards

• Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with an approved product, ONPATTRO, and a robust pipeline.
• Ionis Pharmaceuticals is another key player in the RNA-targeted therapeutics space, focusing on antisense oligonucleotide (ASO) technology.
• Arrowhead Pharmaceuticals is developing RNAi-based therapies using its proprietary Targeted RNAi Molecule (TRiM) platform.
• Dicerna Pharmaceuticals (acquired by Novo Nordisk) is focused on developing RNAi therapies using its GalXC platform.
• Silence Therapeutics' mRNAi GOLD platform and its focus on liver-targeted siRNA delivery differentiate it from some competitors.
• The company's clinical trial results for divesiran and zerlasiran are being compared to existing treatments and emerging therapies in their respective indications.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through successful development and commercialization of product candidates.
• Employees: Continued employment and potential for career growth within the company.
• Patients: Potential for new and improved treatments for cardiovascular, hematology, and rare diseases.
• Collaborators: Continued collaboration and potential for future partnerships.
• Creditors: Ability to meet financial obligations.

Next Steps

• Continue Phase 2 clinical trial of divesiran in PV patients, with full enrollment anticipated by year-end 2025.
• Pursue global partnership discussions for potential Phase 3 development of zerlasiran.
• Advance undisclosed preclinical programs from the mRNAi GOLD platform.
• Plan Phase 1 clinical trial of SLN548 for complement-mediated diseases for the second half of 2025.
• Present Phase 1 data from the SANRECO clinical trial at medical congresses in 2025.

Key Dates